Renalytix (

RENX · AIM · Health Care · mcap £36m · 6.0p 4 open situations →

Beta Briefing, track record and signals & risks are not ready for Renalytix ( yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

2026 Strategic partnerships and EMR rollout 1 director buying Fundraise and debt conversion Two-year outcomes data and CE marking

Open · 4

Transformational contract / build-out◷ in 158 days

Strategic partnerships and EMR rollout

Funding secured; interface build pending

Renalytix signed a multi-year national distribution deal with Quest Diagnostics on 1 September 2026, with physician ordering expected in Q1 2027 and a target of 25,000 tests in 2027. The oversubscribed fundraise now funds the operational pivot to national access and logistics. Revenue still lags, since availability starts only in 2027.

Next: Quest ordering availability · 31 Mar 2027

3 Sep 2026 Funding secured; interface build pending
1 Sep 2026 Funding raised; integration pending
1 Sep 2026 Agreement signed; integration pending
26 Mar 2026 Five integrations live, eight more in deployment

Open the full view – chart and every step →

Insider conviction

1 director buying

£70k in 1 buy

2 Oct 2026 Harwood Capital LLP* £70k

Open the full view – chart and every step →

Dilutive fundraise

Fundraise and debt conversion

Retail offer open; first tranche admission pending

Renalytix launched a bookbuild on 1 September 2026 at 6p, a premium to the market price. It funds the Quest Diagnostics rollout and converts the Heights bonds to equity. The bookbuild closed oversubscribed with £10.1m raised, and Heights holds no debt claim. A WRAP retail offer of up to £1.0m at 6p now opens, closing 7 September. The second tranche needs a General Meeting.

Size: £10.1m gross placing at 6p; up to £1.0m WRAP Retail Offer
Shares: 168,366,151 new shares plus 57,729,741 Conversion Shares to Heights
First tranche: 109,082,253 Placing Shares plus 57,729,741 Conversion Shares; admission 8 September 2026
Second tranche: Second Tranche Placing, Subscription and Retail Offer Shares; needs General Meeting; admission about 29 September 2026
Next milestone: Retail offer result expected on or around 8 September 2026
Insiders: Directors and PDMRs subscribed US$303,366 in total; 6-month lock-in

3 Sep 2026 Retail offer open; first tranche admission pending
3 Sep 2026 Bookbuild closed oversubscribed; first tranche admission pending
1 Sep 2026 Bookbuild open; first tranche admission expected 7 September

Open the full view – chart and every step →

Project milestones

Two-year outcomes data and CE marking

Submitted for publication; CE review progressing

Next: Publish two-year outcomes study; CE marking review completion by end FY26

26 Mar 2026 Submitted for publication; CE review progressing

Open the full view – chart and every step →

Company filings. Not investment advice.